摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-benzyl-3-(4-chlorophenyl)-N-cyclopropyl-N,4-dimethyl-5-(trifluoromethyl)-1H-pyrrole-2-carboxylic acid amide | 1574110-85-2

中文名称
——
中文别名
——
英文名称
1-benzyl-3-(4-chlorophenyl)-N-cyclopropyl-N,4-dimethyl-5-(trifluoromethyl)-1H-pyrrole-2-carboxylic acid amide
英文别名
1-benzyl-3-(4-chlorophenyl)-N-cyclopropyl-N,4-dimethyl-5-(trifluoromethyl)pyrrole-2-carboxamide
1-benzyl-3-(4-chlorophenyl)-N-cyclopropyl-N,4-dimethyl-5-(trifluoromethyl)-1H-pyrrole-2-carboxylic acid amide化学式
CAS
1574110-85-2
化学式
C24H22ClF3N2O
mdl
——
分子量
446.9
InChiKey
VWVFGOTUVRIFAA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.1
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    25.2
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • [EN] FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES<br/>[FR] PYRROLE CARBOXAMIDES SUBSTITUÉS PAR UN FLUOROMÉTHYLE
    申请人:GRUENENTHAL GMBH
    公开号:WO2014032801A1
    公开(公告)日:2014-03-06
    The invention relates to pyrrole carboxamides bearing a fluoromethyl- moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    这项发明涉及带有甲基基团的吡咯羧酰胺作为电压门控钙通道阻滞剂,以及含有这些化合物的药物组合物,还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
  • FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES
    申请人:GRUNENTHAL GMBH
    公开号:US20140066426A1
    公开(公告)日:2014-03-06
    The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    这项发明涉及带有甲基基团的吡咯酮羧酰胺作为电压门控钙通道阻滞剂,以及含有这些化合物的药物组合物,还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
  • Fused Imidazole Derivatives Useful as IDO Inhibitors
    申请人:NewLink Genetics Corporation
    公开号:US20140066625A1
    公开(公告)日:2014-03-06
    Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleanine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.
    目前提供IDO抑制剂及其制药组合物,用于调节吲哚胺2,3-双加氧酶的活性;治疗吲哚胺2,3-双加氧酶(IDO)介导的免疫抑制;治疗受益于抑制吲哚胺-2,3-双加氧酶酶活性的医疗状况;增强包括给予抗癌药物在内的抗癌治疗的有效性;治疗与癌症相关的肿瘤特异性免疫抑制;以及治疗与传染病相关的免疫抑制。
  • COMPOSITIONS COMPRISING FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS
    申请人:Newlink Genetics Corporation
    公开号:EP3348558A1
    公开(公告)日:2018-07-18
    Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated inimunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.
    目前提供的IDO抑制剂及其药物组合物可用于调节吲哚胺-2,3-二氧化酶的活性;治疗吲哚胺-2,3-二氧化酶(IDO)介导的免疫抑制;治疗从抑制吲哚胺-2,3-二氧化酶酶活性中获益的病症;提高抗癌治疗的有效性,包括施用抗癌剂;治疗与癌症相关的肿瘤特异性免疫抑制;以及治疗与传染性疾病相关的免疫抑制。
  • IDO inhibitors
    申请人:NewLink Genetics Corporation
    公开号:US10233190B2
    公开(公告)日:2019-03-19
    Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.
    目前提供的 IDO 抑制剂及其药物组合物可用于调节吲哚胺-2,3-二氧 化酶的活性;治疗吲哚胺-2,3-二氧 化酶(IDO)介导的免疫抑制;治疗从抑制吲哚胺-2,3-二氧 化酶酶活性中获益的病症;提高抗癌治疗的有效性,包括施用抗癌剂;治疗与癌症相关的肿瘤特异性免疫抑制;以及治疗与传染病相关的免疫抑制。
查看更多